Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
CDx Diagnostics® logo — Empowering Physicians to Preempt Cancer ℠

CDx Diagnostics®

Empowering Physicians to Preempt Cancer ℠

Founded 2010 127 employees Venture round Biopharma, Biotechnology +3

General Information

Company Name CDx Diagnostics®
Founded Year 2010
Employees 127
Industries Biopharma, Biotechnology, Design +2
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with CDx Diagnostics®. To contact CDx Diagnostics®, visit cdxdiagnostics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does CDx Diagnostics® compare?

A PDF of CDx Diagnostics® and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting CDx Diagnostics® soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About CDx Diagnostics®

The mission of CDx Diagnostics® is to provide clinicians with easily implemented, cost-effective tools to preempt cancer through enhanced detection of precancerous cellular changes. This is accomplished by a proprietary diagnostic platform that synthesizes computer imaging, artificial intelligence, molecular biology and three-dimensional cytopathology to detect precancerous change earlier and more reliably than prior methods. CDx tests require only a few minutes of practice time, are highly cost-effective, widely reimbursed, and address a recognized critical gap in the current diagnostic standard of care that results in thousands of otherwise unnecessary cancer deaths each year. Routine clinical use of CDx testing has already detected thousands of precancerous cells that would otherwise have been missed in time for effective endoscopic treatment and application of the CDx diagnostic platform to prevent cancers of the bile duct, stomach, and IBD affected colon is currently in progress. About WATS3D WATS3D addresses the major inadequacies inherent in current random forceps biopsy testing of the esophagus. In just a few minutes, endoscopists can easily obtain a wide area, full-thickness transepithelial specimen for computer-assisted 3D laboratory analysis prior to diagnosis by any WATS3D certified pathologist. In large multicenter clinical trials, WATS3D has been found to significantly increase the detection rate of both Barrett’s esophagus and esophageal dysplasia. The high sensitivity and inter-observer agreement of WATS3D is due to the larger tissue area sampled, and the proprietary 3-Dimensional computer imaging system that is based on an artificial intelligence algorithm developed as part of the U.S. Strategic Defense Initiative missile defense program. To learn more about WATS3D, visit www.wats3d.com.

No funding data available for CDx Diagnostics® yet.

FAQ About CDx Diagnostics®

Empowering Physicians to Preempt Cancer ℠
CDx Diagnostics® was founded in 2010.
CDx Diagnostics® operates in Biopharma, Biotechnology, Design, Health Care and Pharmaceutical.
CDx Diagnostics® has approximately 127 employees.

We're actively collecting intelligence on CDx Diagnostics®.

Source: BounceWatch company record for CDx Diagnostics®, https://bouncewatch.com/company/cdx-diagnostics, updated 7 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes